详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Huafeng Wang[1,2,3,4] ; Chang Yang[1,5] ; Ting Shi[1,2,3] ; Yi Zhang[1,2,3] ; Jiejing Qian[1,2,3] ; Yungui Wang[1,2,3] ; Yongxian Hu [3,6] ; Liping Mao[1,2,3] ; Xiujin Ye[1,2,3] ; Fang Liu[7] ; Zhenfang Xi[8] ; Lihong Shou[9] ; Caiyun Fu[10] ; Hua Naranmandura[1,5] ; Jie Jin [1,2,3,4] ; Hong-Hu Zhu [1,2,3,4,11] ;

机构： [1]Department of Hematology, The First Affiliated Hospital, ZhejiangUniversity School of Medicine, Hangzhou, PR China [2]ZhejiangProvincial Key Lab of Hematopoietic Malignancy, Zhejiang University,Hangzhou, Zhejiang, PR China [3]Institute of Hematology, ZhejiangUniversity, Hangzhou, Zhejiang, PR China [4]Zhejiang UniversityCancer Center, Hangzhou, Zhejiang, PR China [5]Department of PublicHealth, Zhejiang University School of Medicine, Hangzhou, PR China [6]Bone Marrow Transplantation Center, the First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, PR China [7]Department of Hematology, Chengdu Military General Hospital,Chengdu, Sichuan, P [R] [C]hina [8]Department of Hematology, LinfenPeople’s Hospital, Linfen, Shanxi, PR China [9]Department ofHematology, The Central Hospital of Huzhou City, Huzhou, People’sRepublic of China [10]College of Life Sciences and Medicine, ZhejiangSci-Tech University, Hangzhou, China [11]Zhejiang Laboratory forSystems & Precision Medicine, Zhejiang University Medical Center,Hangzhou, China

出处：

DOI：

ISSN：

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 1 区

医学

小类 | 2 区血液学 2 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区血液学 1 区肿瘤学

JCR分区：

出版当年[2022]版：

Q1 HEMATOLOGY Q1 ONCOLOGY

最新[2023]版：

Q1 HEMATOLOGY Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Department of Hematology, The First Affiliated Hospital, ZhejiangUniversity School of Medicine, Hangzhou, PR China [2]ZhejiangProvincial Key Lab of Hematopoietic Malignancy, Zhejiang University,Hangzhou, Zhejiang, PR China [3]Institute of Hematology, ZhejiangUniversity, Hangzhou, Zhejiang, PR China [4]Zhejiang UniversityCancer Center, Hangzhou, Zhejiang, PR China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Hematology, The First Affiliated Hospital, ZhejiangUniversity School of Medicine, Hangzhou, PR China [2]ZhejiangProvincial Key Lab of Hematopoietic Malignancy, Zhejiang University,Hangzhou, Zhejiang, PR China [3]Institute of Hematology, ZhejiangUniversity, Hangzhou, Zhejiang, PR China [4]Zhejiang UniversityCancer Center, Hangzhou, Zhejiang, PR China [5]Department of PublicHealth, Zhejiang University School of Medicine, Hangzhou, PR China [11]Zhejiang Laboratory forSystems & Precision Medicine, Zhejiang University Medical Center,Hangzhou, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia.

文献详情